

Appl. No. 09/489,667
Reply to Office action of July 9, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-68. (Cancelled)

69. (Currently amended) An agent for treating pain comprising a modified clostridial neurotoxin, wherein the modified clostridial neurotoxin has been modified is obtained by removing or modifying an Hc domain of a native clostridial neurotoxin to form an intermediate clostridial neurotoxin and covalently coupling or recombinantly fusing substance P to the intermediate clostridial neurotoxin so that the modified clostridial neurotoxin no longer binds to neurotoxin receptors at a neuromuscular junction with the same affinity as [[a]] the native clostridial neurotoxin.

70. (Currently amended) The agent of claim 69 wherein the clostridial neurotoxin is produced by obtained from an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum and Clostridial tetani.

71. (Previously presented) The agent of claim 69 wherein the clostridial neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C₁, serotype D, serotype E, serotype F and serotype G.

BEST AVAILABLE COPY

Appl. No. 09/489,667

Reply to Office action of July 9, 2004

72. (Previously presented) The agent of claim 69 wherein the clostridial neurotoxin is botulinum toxin serotype A.

73. (Previously presented) The agent of claim 69 wherein the clostridial neurotoxin comprises an H_N and an L chain.

74. (Currently amended) The agent of claim 73 wherein the H_N is ~~produced by~~ obtained from an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum and Clostridial tetani.

75. (Currently amended) The agent of claim 73 wherein the L chain is ~~produced by~~ obtained from an organism selected from the group consisting of Clostridial beratti, Clostridial butyricum, Clostridial botulinum, and Clostridial tetani.

76. (Previously presented) The agent of claim 73 wherein the H_N is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C₁, serotype D, serotype E, serotype F and serotype G.

77. (Previously presented) An agent for treating pain comprising a botulinum toxin, without an H_C that binds to receptors at the neuromuscular junction with the same affinity as native botulinum toxin, covalently coupled to substance P.

78. (Previously presented) An agent for treating pain comprising a botulinum toxin serotype A, without a functional H_C domain, covalently coupled to substance P.

Appl. No. 09/489,667

Reply to Office action of July 9, 2004

79. (Previously presented) An agent for treating pain comprising a botulinum toxin covalently coupled to substance P, wherein an H_c of the toxin has been removed.

80. (Currently amended) An agent for treating pain comprising a botulinum toxin serotype A covalently coupled to substance P, wherein an H_c of the toxin has been removed, the agent treats pain by acting on [[the]] a projection neuron.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.